Zynex, Inc. (OTCMKTS:ZYXI) Files An 8-K Entry into a Material Definitive Agreement
ITEM 1.01
On March 11, 2019, Zynex, Inc. (Company) entered into an Amendment to its Sublease Agreement (Sublease) with CSG Systems, Inc. (Sublandlord) for an additional 21,420 square feet of office space at its current headquarters location at Two Maroon Circle, located at 9555 Maroon Circle, Englewood, CO 80112. The term of sublease for the additional space begins on the later of the completion of the Expansion Work (as defined in the Sublease) or June 1, 2019 and runs through June 30, 2023, with an option to extend the term for an additional two years through June 30, 2025. During the first seven months of the Amendment to the Sublease, the rent per square foot is $10.00, increasing to $20.75 from January 1, 2020 through October 31, 2020. Annual periods beginning November 1, 2020, the price per square foot increases by an additional $1 per square foot. The Company is also obligated to pay its proportionate share of building operating expenses. The Company has an option to Sublease additional space in the event the Sublandlord seeks to sublet adjacent space in the building. The Amendment to the Sublease is subject to customary lease terms and conditions, including provisions relating to mandatory insurance and remedies upon default.
| 10.1 | Third Amendment to the Sublease Agreement between Zynex, Inc. and CSG Systems, Inc. |
| 99.1 | Press Release |
ZYNEX INC Exhibit
EX-10.1 2 tv516071_ex10-1.htm EXHIBIT 10.1 EXHIBIT 10.1 THIRD AMENDMENT TO SUBLEASE This THIRD AMENDMENT TO SUBLEASE (this “Amendment”) is entered into and made effective as of the 11th day of March,…
To view the full exhibit click here
About Zynex, Inc. (OTCMKTS:ZYXI)
Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.
